Health Outcomes, Discrimination, and Stigma Among Sexual and Gender Minority People With Inflammatory Bowel Disease
Inflammatory Bowel Diseases · 2025
DOI: 10.1093/ibd/izaf054 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Kira L Newman und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Michigan, Ann Arbor, MI, USA. Hauptthemen laut MEDLINE: Social Stigma, Sexual and Gender Minorities, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Crohn's and Colitis Foundation, National Institute for Diabetes and Digestive and Kidney Diseases of the, NIH HHS.
Abstract (Originalsprache)
Background
Sexual and gender minority (SGM) individuals often experience more discrimination and worse health than non-SGM people. Less is known about SGM individuals with inflammatory bowel disease (IBD). We studied IBD outcomes, discrimination, illness-related stigma, and SGM status in a cross-sectional survey.
Methods
In total, 1586 IBD Partners e-cohort participants self-reported sexual orientation, gender identity, and prior IBD treatment. They completed the Short Crohn’s Disease Activity Index or Simple Clinical Colitis Activity Index, the Everyday Discrimination Scale, and the Paradox of Self Stigma (PASS-24) scale. We performed regression analyses controlling for age, race, disease duration, and IBD type.
Results
SGM people were 7.8% (n = 124) of the cohort. SGM participants were younger than non-SGM participants (median age 40 vs. 54 years, P < .001). Among SGM individuals, 67% (n = 74) were in remission based on disease activity scores. Among non-SGM individuals, 74% (n = 936) were in remission (P = .097). Similar proportions of SGM and non-SGM persons reported prior IBD-related hospitalization (40% vs. 37%, P = .426; adjusted odds ratio [aOR] 0.95, 95% confidence interval [CI], 0.62-1.45) and IBD-related surgery (52% vs. 54%, P = .707, aOR 1.25, 95% CI, 0.81-1.94). SGM respondents reported more discrimination (71% vs. 47%, P < .001), and 43% of SGM individuals reported healthcare-related discrimination versus 21% of non-SGM individuals (P < .001). SGM persons also endorsed more internalized stigma (median PASS-24 scores 53 vs. 47, P = .026).
Conclusions
SGM individuals with IBD are more likely to experience discrimination, including in healthcare, and illness-related stigma. These may significantly impact the quality of life and should be considered in the care of SGM people with IBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, University of Michigan, Ann Arbor, MI, USA.
- Department of Public Health, Wayne State University, Detroit, MI, USA.
- Department of Medicine, University of North Carolina, Chapel Hill, NC, USA.
ORCID-Profile: Kira L Newman, Patricia A Wren, Millie D Long, Peter D R Higgins
Förderung
- Crohn's and Colitis Foundation
- National Institute for Diabetes and Digestive and Kidney Diseases of the
- NIH HHS
- American College of Gastroenterology Junior Faculty Career Development Award
- Crohn’s and Colitis Foundation
- National Institutes of Health
Zitieren
APA
Newman, K. L., Wren, P. A., Long, M. D., & Higgins, P. D. R. (2025). Health Outcomes, Discrimination, and Stigma Among Sexual and Gender Minority People With Inflammatory Bowel Disease. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izaf054
Vancouver
Newman KL, Wren PA, Long MD, Higgins PDR. Health Outcomes, Discrimination, and Stigma Among Sexual and Gender Minority People With Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izaf054
BibTeX
@article{Newman2025,
author = {Newman, Kira L and Wren, Patricia A and Long, Millie D and Higgins, Peter D R},
title = {Health Outcomes, Discrimination, and Stigma Among Sexual and Gender Minority People With Inflammatory Bowel Disease},
journal = {Inflammatory Bowel Diseases},
year = {2025},
doi = {10.1093/ibd/izaf054}
}
EUVIMED